aibioZOMDF Zomedica Corp.
Zomedica (ZOMDF) news
Top story · Aug 5, 2026 · SEC filing 8-K
Zomedica reports results
(the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026.
Latest Zomedica news
We have not published a story on Zomedica yet. When there is news, it will appear here.
What Zomedica does
Zomedica Corp. is an animal health company that creates and markets diagnostic and therapeutic products for companion animals, including dogs, cats and horses, with a focus on the needs of clinical veterinarians. The company says it has grown primarily through acquisitions and is currently commercializing six product lines of diagnostic and therapeutic devices. Its TRUFORMA Bulk Acoustic Wave point-of-care diagnostic platform is marketed with full diagnostic panels, including assays for equine endogenous ACTH. Other launched products include the VETGuardian PLUS Zero Touch vital signs remote monitoring system, the TRUVIEW digital microscopy platform, and VETIGEL, a fast-acting hemostatic gel licensed from Cresilon, Inc. Its manufacturing and distribution operations in Roswell, Georgia and Plymouth, Minnesota have ISO 13485 certification. The company also says it can use its manufacturing and engineering capabilities to provide development services beyond animal health. Its common shares were delisted from NYSE American in March 2025 and began trading on the OTCQB Market under the symbol ZOMDF.
| Product or program | What it is | Stage |
|---|---|---|
| TRUFORMA | Bulk Acoustic Wave point-of-care diagnostic platform for animal health | marketed |
| VETGuardian PLUS Zero Touch | Vital signs remote monitoring system for veterinary use | launched |
| TRUVIEW | Digital microscopy platform | launched |
| VETIGEL | Fast-acting hemostatic gel licensed from Cresilon, designed to stop bleeding | launched |
Zomedica annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $7.2 million | $7.3 million |
| Net income (loss) | -$81.9 million | -$47.0 million |
| Cash from operations | -$17.6 million | -$23.6 million |
| Cash and equivalents | $9.0 million | $7.0 million |
Questions about Zomedica
What is the ticker symbol of Zomedica?
Zomedica Corp. trades under the ticker ZOMDF on OTC.
Where is Zomedica listed?
Zomedica Corp. is listed on OTC.
What is the SEC CIK of Zomedica?
The SEC Central Index Key (CIK) for Zomedica Corp. is 1684144. Its filings are on SEC EDGAR.
How many shares does Zomedica have outstanding?
979,949,668 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is Zomedica listed under?
Our directory records Zomedica Corp. under United States.
What does Zomedica do?
Our directory classifies Zomedica Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Zomedica?
The ISIN recorded for Zomedica Corp. is CA98980M1095.
Does aibio.space cover Zomedica?
aibio.space lists Zomedica Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Zomedica incorporated?
SEC records list its state or country of incorporation as A0.
What does Zomedica develop?
Zomedica Corp. is an animal health company that creates and markets diagnostic and therapeutic products for companion animals, including dogs, cats and horses, with a focus on the needs of clinical veterinarians. The company says it has grown primarily through acquisitions and is currently commercializing six product lines of diagnostic and therapeutic devices.
What is TRUFORMA from Zomedica?
TRUFORMA: Bulk Acoustic Wave point-of-care diagnostic platform for animal health Stage: marketed.
What is VETGuardian PLUS Zero Touch from Zomedica?
VETGuardian PLUS Zero Touch: Vital signs remote monitoring system for veterinary use Stage: launched.
Is Zomedica profitable?
Zomedica Corp. reported a net loss of $81.9 million for the fiscal year ended Dec 31, 2025, and used $17.6 million of cash in operations, per its annual report to the SEC.
How much does Zomedica spend on research and development?
$7.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Zomedica have?
$7.2 million in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Zomedica
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Zomedica Corp.
- CIK
- 1684144
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ZOMDF (OTC)
- State or country of incorporation
- A0
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1101 TECHNOLOGY DRIVE, ANN ARBOR, MI, 48108
- Phone
- (734) 369-2555
- Shares outstanding
- 979,949,668 as of 2026-08-05 (10-Q filed 2026-08-05)
- Former names
- Zomedica Pharmaceuticals Corp.
Recent filings
Listing details
- Company
- Zomedica Corp.
- Ticker
- ZOMDF
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- CA98980M1095
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction